Edgar Filing: BIENAIME JEAN JACQUES - Form 4

Form 4 March 13, 2 FORN	A 4 UNITED	STATES SECI	JRITIES A Vashington			ANGE CO	OMMISSION	OMB AF OMB Number:	PROVAL 3235-0287	
Check t if no lon subject Section Form 4 Form 5 obligati may con <i>See</i> Inst 1(b).	nger to 16. or Filed pu ons ntinue.	rsuant to Sectior (a) of the Public	OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 9 Section 16(a) of the Securities Exchange Act of 1934, e Public Utility Holding Company Act of 1935 or Section a) of the Investment Company Act of 1940						January 31, 2005 d average ours per e 0.5	
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> BIENAIME JEAN JACQUES			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [BMRN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 03/09/2012				_X_ Director 10% Owner _X_ Officer (give title Other (specify below) below) Chief Executive Officer			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
NOVATO	, CA 94949					Ē	erson	ore than One Rej	porting	
(City)	(State)	(Zip) Ta	able I - Non-I	Derivative	Secu	rities Acqui	red, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year	Code		ed of ((D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	03/09/2012	03/09/2012	М	15,000	A	\$ 6.47	129,093	D		
Common Stock	03/09/2012	03/09/2012	S	15,000	D	\$ 34.4578	114,093	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: BIENAIME JEAN JACQUES - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy)	\$ 6.47	03/09/2012	03/09/2012	М	15,000	05/11/2006(2)	05/10/2015	Common Stock	15,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949	Х		Chief Executive Officer			
Signatures						
/s/ Laura Randall Woodhead, Attorney-in-Fact	03/1	3/2012				
<u>**</u> Signature of Reporting Person	D	ate				
Evenlage attack of Decomposition	_					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price in Column 4 is a weighted average price. The prices actually received ranged from \$34.20 to \$34.71. The reporting person will
 (1) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (2) Original option grant vested 1/3 each on May 11, 2006, May 11, 2007, and May 11, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.